Liquid-liquid phase separation in diseases.
RNA methylation
cancer
neurodegenerative disease
phase separation
stress granule
Journal
MedComm
ISSN: 2688-2663
Titre abrégé: MedComm (2020)
Pays: China
ID NLM: 101769925
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
25
12
2023
revised:
31
05
2024
accepted:
03
06
2024
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
epublish
Résumé
Liquid-liquid phase separation (LLPS), an emerging biophysical phenomenon, can sequester molecules to implement physiological and pathological functions. LLPS implements the assembly of numerous membraneless chambers, including stress granules and P-bodies, containing RNA and protein. RNA-RNA and RNA-protein interactions play a critical role in LLPS. Scaffolding proteins, through multivalent interactions and external factors, support protein-RNA interaction networks to form condensates involved in a variety of diseases, particularly neurodegenerative diseases and cancer. Modulating LLPS phenomenon in multiple pathogenic proteins for the treatment of neurodegenerative diseases and cancer could present a promising direction, though recent advances in this area are limited. Here, we summarize in detail the complexity of LLPS in constructing signaling pathways and highlight the role of LLPS in neurodegenerative diseases and cancers. We also explore RNA modifications on LLPS to alter diseases progression because these modifications can influence LLPS of certain proteins or the formation of stress granules, and discuss the possibility of proper manipulation of LLPS process to restore cellular homeostasis or develop therapeutic drugs for the eradication of diseases. This review attempts to discuss potential therapeutic opportunities by elaborating on the connection between LLPS, RNA modification, and their roles in diseases.
Identifiants
pubmed: 39006762
doi: 10.1002/mco2.640
pii: MCO2640
pmc: PMC11245632
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e640Informations de copyright
© 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.